Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
Latest Information Update: 30 Aug 2024
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 21 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 28 Jun 2023 Planned End Date changed from 14 Feb 2024 to 14 Feb 2025.
- 28 Jun 2023 Planned primary completion date changed from 14 Feb 2024 to 14 Feb 2025.